Aller au contenu principal
Profil bibliographique

Geoffrey Owen Littlejohn

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

241Publications signalées
6602Citations signalées
2Affiliations récentes

Les institutions déclarées

Les domaines associés

Fibromyalgia and Chronic Fatigue Syndrome ResearchRheumatoid Arthritis Research and TherapiesMusculoskeletal pain and rehabilitationSystemic Lupus Erythematosus ResearchSpondyloarthritis Studies and Treatments

Les publications récentes

Accès ouvert 2025 erratum OpenAlex

Correction: Real‑World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis

Peter P. Youssef, Sabina Ciciriello, Talib Tahir, Joanna Leadbetter et autres

In the sentence beginning 'Median persistence (Kaplan-Meier) and effectiveness…' of the Methods section in Abstract, the text '(Kaplan-Meier)' should have read '(Kaplan-Meier, log rank test)'.Few terms were missing in the Results section of the Abstract and it was incorrect as 'Results: In …

au (code pays fourni par la source)

0 citations Rheumatology and Therapy
Accès ouvert 2025 article OpenAlex

Neuroinflammatory and Immunological Aspects of Fibromyalgia

Kate E Findeisen, Emma Guymer, Geoffrey Owen Littlejohn

Fibromyalgia is a common, high-impact condition of chronic widespread pain and sensory dysfunction associated with altered central and peripheral sensory processing. A growing body of evidence supports the role of neuroinflammation and immune changes in fibromyalgia, and a narrative review of this …

au (code pays fourni par la source)

48 citations Brain Sciences
Accès ouvert 2025 article OpenAlex

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis

Peter P. Youssef, Sabina Ciciriello, Talib Tahir, Joanna Leadbetter et autres

This study sought to describe treatment patterns, persistence, and effectiveness of upadacitinib (UPA) alone and compared to other Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) in patients with rheumatoid arthritis (RA). This retrospective, non-interventional study used the OPAL dataset, …

au (code pays fourni par la source)

15 citations Rheumatology and Therapy
Accès ouvert 2024 article OpenAlex

Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022

Geoffrey Owen Littlejohn, Nithila Anbumurali, Catherine P. O’Sullivan, Tegan Smith et autres

Abstract Objective To describe the trends in remission rates among RA patients in the OPAL dataset, spanning from 2009 to 2022, and provide insights into the effectiveness of evolving RA management approaches in real-world clinical settings. Methods Patients with a physician diagnosis …

au (code pays fourni par la source)

3 citations Clinical Rheumatology
Accès ouvert 2024 article OpenAlex

Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia

Geoffrey Owen Littlejohn, Joanna Leadbetter, Belinda Butcher, Marie Feletar et autres

OBJECTIVES: To describe treatment patterns and persistence of tofacitinib, interleukin 17 inhibitors (IL-17Ai) and tumour necrosis factor inhibitors (TNFi), in patients with psoriatic arthritis (PsA). METHODS: Data from adult patients with PsA and who had received at least one prescription of tofacitinib, …

au (code pays fourni par la source)

2 citations Clinical Rheumatology
2023 article OpenAlex

Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost‐savings

Claire T. Deakin, Geoffrey Owen Littlejohn, Hedley Griffiths, Sabina Ciciriello et autres

BACKGROUND AND AIMS: This study aimed to assess the comparative effectiveness of the etanercept (ETN) originator (Enbrel) and ETN biosimilar SB4 (Brenzys) as first-line treatment in patients with rheumatoid arthritis (RA), while also exploring the potential cost-savings associated with this approach in …

gb, au (code pays fourni par la source)

4 citations Internal Medicine Journal
Accès ouvert 2023 article OpenAlex

Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset

Sabina Ciciriello, Geoffrey Owen Littlejohn, Tamás Treuer, Kathryn Gibson et autres

OBJECTIVES: To describe use and treatment persistence for Janus kinase inhibitors (JAKi) in rheumatoid arthritis (RA) by line of therapy, and the mechanism of action for the drug switched to after JAKi discontinuation. METHODS: This was a retrospective, observational analysis using the …

au, us, gb (code pays fourni par la source)

5 citations Clinical and Experimental Rheumatology
Accès ouvert 2023 article OpenAlex

Significant use of non‐evidence‐based therapeutics in a cohort of Australian fibromyalgia patients

Zachary Warren, Emma Guymer, Veronica Mezhov, Geoffrey Owen Littlejohn

BACKGROUND: Fibromyalgia is a common condition characterised by chronic widespread musculoskeletal pain and central sensitivity features. Appropriate management requires a multidisciplinary approach prioritising non-pharmacological strategies. Evidence-based fibromyalgia medications are not always easily available, effective or tolerated. AIM: To characterise actual medication usage …

au (code pays fourni par la source)

3 citations Internal Medicine Journal
Accès ouvert 2023 article OpenAlex

Burden of disease and real-world treatment patterns of patients with systemic lupus erythematosus in the Australian OPAL dataset

Sabina Ciciriello, Geoffrey Owen Littlejohn, Catherine P. O’Sullivan, Tegan Smith et autres

OBJECTIVE: To describe the demographics, disease burden and real-world management of patients with systemic lupus erythematosus (SLE) in Australian community practice. METHODS: Patients with a physician diagnosis of SLE and at least 1 visit between 1 January 2009 and 31 March 2021 …

au, gb (code pays fourni par la source)

6 citations Clinical Rheumatology
Accès ouvert 2023 article OpenAlex

Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia

Claire T. Deakin, Bianca Lucia De Stavola, Geoffrey Owen Littlejohn, Hedley Griffiths et autres

Importance: There is a need for observational studies to supplement evidence from clinical trials, and the target trial emulation (TTE) framework can help avoid biases that can be introduced when treatments are compared crudely using observational data by applying design principles for …

gb, au (code pays fourni par la source)

15 citations JAMA Network Open

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.